These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25628060)

  • 1. Translation from clinical trials to routine practice: how to demonstrate community benefit.
    Roder D; Buckley E
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):1-3. PubMed ID: 25628060
    [No Abstract]   [Full Text] [Related]  

  • 2. Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice.
    Lok SW; Wong HL; Kosmider S; Field K; Tie J; Desai J; Bae S; Tacey M; Skinner I; Jones I; Gibbs P
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):361-7. PubMed ID: 25131961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
    Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
    Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring the colorectal cancer disease assessment to the treatment strategy.
    Deming DA
    Gut; 2018 Jun; 67(6):996-997. PubMed ID: 29269439
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
    Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
    Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?
    Bria E; Di Maio M; Cuppone F; Nisticò C; Cognetti F; Giannarelli D
    J Clin Oncol; 2007 Feb; 25(5):605-6; author reply 606-7. PubMed ID: 17290074
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chemotherapy of inoperable colorectal cancer].
    Herrmann R
    Wien Med Wochenschr; 1988 Jul; 138(13):310-3. PubMed ID: 3055690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined therapy of rectal tumors: the chemotherapy].
    Di Bartolomeo M; Bajetta E; Beretta E; Buzzoni R
    Tumori; 2001; 87(1 Suppl 1):S31-2. PubMed ID: 11300018
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs of chemotherapy in the treatment of colorectal cancer.
    Jansman FG; Postma MJ
    Eur J Health Econ; 2006 Jun; 7(2):145-6. PubMed ID: 16699776
    [No Abstract]   [Full Text] [Related]  

  • 11. [Regional adjuvant chemotherapy in colorectal cancer].
    Shparyk IaV; Bilyns'kyĭ BT
    Klin Khir; 1995; (9-10):41-5. PubMed ID: 8697216
    [No Abstract]   [Full Text] [Related]  

  • 12. Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.
    Kerbel RS; Grothey A
    Nat Rev Clin Oncol; 2015 Jun; 12(6):313-4. PubMed ID: 25963090
    [No Abstract]   [Full Text] [Related]  

  • 13. Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
    Paolicchi E; Vivaldi C; De Gregorio V; Crea F; Fornaro L; Masi G; Loupakis F; Graziano F; Ronzoni M; Ricci V; Falcone A; Danesi R
    Oncology; 2016; 91(5):283-288. PubMed ID: 27577551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimum chemotherapy for metastatic colorectal cancer.
    Bendell J
    Lancet; 2006 Dec; 368(9552):2039-41. PubMed ID: 17161715
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials referral resource.
    Cheson BD
    Oncology (Williston Park); 1990 Nov; 4(11):72. PubMed ID: 2150327
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination chemotherapy for advanced colorectal cancer.
    Mason M; Johnson P; Rudd R;
    Br J Cancer; 2003 Apr; 88(7):1152-3; author reply 1153-5. PubMed ID: 12671718
    [No Abstract]   [Full Text] [Related]  

  • 17. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
    Satoh T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time.
    Satta F; Franchi F
    J Chemother; 1997 Dec; 9(6):431-5. PubMed ID: 9491844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of colorectal cancer in older patients.
    Xiao H; Lichtman SM
    Oncology (Williston Park); 2006 Jun; 20(7):741-50; discussion 750, 755-6. PubMed ID: 16841797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.